Gene therapy for type 1 diabetes: Is it ready for the clinic?

Antonella D'Anneo; Pleunie Rood; Rita Bottino; A. N. Balamurugan; Jing He; Nick Giannoukakis

doi:10.1385/ir:36:1:83

Gene therapy for type 1 diabetes: Is it ready for the clinic?

Antonella D'Anneo
, Pleunie Rood
, Rita Bottino
, A. N. Balamurugan
, Jing He
, Nick Giannoukakis^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › Academic › peer-review

5 Citations (Scopus)

Abstract

This review, in addition to updating the growing list of type 1 diabetes- relevant gene therapies, offers an outline of short-term objectives that can readily be met to move, at least, adenoviral and adeno-associated viral-based protocols into the clinic, first as a means of facilitating islet allografts as well as platforms with which to introduce immunoregulatory transgenes. A wide array of genes have been tested to restore insulin production, to drive the differentiation of insulin-producing progenitors, and to confer immunosuppression in an antigen- and tissue-restricted manner.

Original language	English
Pages (from-to)	83-89
Number of pages	7
Journal	Immunologic Research
Volume	36
Issue number	1-3
DOIs	https://doi.org/10.1385/ir:36:1:83
Publication status	Published - Sept 2006
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1385/ir:36:1:83

Cite this

@article{140c324ca91b4302ade4f7a269329274,

title = "Gene therapy for type 1 diabetes: Is it ready for the clinic?",

abstract = "This review, in addition to updating the growing list of type 1 diabetes- relevant gene therapies, offers an outline of short-term objectives that can readily be met to move, at least, adenoviral and adeno-associated viral-based protocols into the clinic, first as a means of facilitating islet allografts as well as platforms with which to introduce immunoregulatory transgenes. A wide array of genes have been tested to restore insulin production, to drive the differentiation of insulin-producing progenitors, and to confer immunosuppression in an antigen- and tissue-restricted manner.",

author = "Antonella D'Anneo and Pleunie Rood and Rita Bottino and Balamurugan, \{A. N.\} and Jing He and Nick Giannoukakis",

year = "2006",

month = sep,

doi = "10.1385/ir:36:1:83",

language = "English",

volume = "36",

pages = "83--89",

journal = "Immunologic Research",

issn = "0257-277X",

publisher = "Springer",

number = "1-3",

}

TY - JOUR

T1 - Gene therapy for type 1 diabetes

T2 - Is it ready for the clinic?

AU - D'Anneo, Antonella

AU - Rood, Pleunie

AU - Bottino, Rita

AU - Balamurugan, A. N.

AU - He, Jing

AU - Giannoukakis, Nick

PY - 2006/9

Y1 - 2006/9

N2 - This review, in addition to updating the growing list of type 1 diabetes- relevant gene therapies, offers an outline of short-term objectives that can readily be met to move, at least, adenoviral and adeno-associated viral-based protocols into the clinic, first as a means of facilitating islet allografts as well as platforms with which to introduce immunoregulatory transgenes. A wide array of genes have been tested to restore insulin production, to drive the differentiation of insulin-producing progenitors, and to confer immunosuppression in an antigen- and tissue-restricted manner.

AB - This review, in addition to updating the growing list of type 1 diabetes- relevant gene therapies, offers an outline of short-term objectives that can readily be met to move, at least, adenoviral and adeno-associated viral-based protocols into the clinic, first as a means of facilitating islet allografts as well as platforms with which to introduce immunoregulatory transgenes. A wide array of genes have been tested to restore insulin production, to drive the differentiation of insulin-producing progenitors, and to confer immunosuppression in an antigen- and tissue-restricted manner.

UR - https://www.scopus.com/pages/publications/33947188722

U2 - 10.1385/ir:36:1:83

DO - 10.1385/ir:36:1:83

M3 - Review article

C2 - 17337769

AN - SCOPUS:33947188722

SN - 0257-277X

VL - 36

SP - 83

EP - 89

JO - Immunologic Research

JF - Immunologic Research

IS - 1-3

ER -

Gene therapy for type 1 diabetes: Is it ready for the clinic?

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this